Tue, Mar 3, 2015, 2:42 AM EST - U.S. Markets open in 6 hrs 48 mins

Recent

% | $
Quotes you view appear here for quick access.

NUO THERAPEUTICS, INC. Message Board

  • realtyanthony13 realtyanthony13 Feb 28, 2014 10:40 AM Flag

    no news for a while where is a new update ? this should fly to .80 with good news

     

    ?

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • .80 is extremely conservative, As I see a move to the $3-4.00 range.. This guy is on our team for a reason.

      Dean Tozer is now on the Cytomedix team, His name is displayed at the JAn SEC release bottom. This fellow drove Shires success with Dermagraft and has some impressive resume..

      Dean Tozer has served as Senior Vice President, Corporate Development at Advanced BioHealing (Now Shire

      Regenerative Medicine) since May 2009. Executive Committee: Dean Tozer

      Senior Vice President, Corporate Developement, Shire Regenerative Medicine
      Dean Tozer has served as Senior Vice President, Corporate Development at Advanced BioHealing (Now Shire Regenerative Medicine) since May 2009. Mr. Tozer joined ABH in June 2006 as Vice President of Marketing and Corporate Development. Prior to ABH, Mr. Tozer was a consultant to the biopharmaceutical industry assisting start-up organizations in developing marketing and commercialization strategies for both pharmaceutical products and biomedical devices. Preceding his consulting career, he spent 10 years in the global pharmaceutical industry, primarily with G.D. Searle & Company, a division of Monsanto, where he had a wide variety of roles in global marketing, sales, business redesign and accounting and finance. Mr. Tozer has also served as an officer and board member of the Alliance for Regenerative Medicine, a non-profit organization. He holds a Bachelor of Commerce degree from Saint Mary’s University in Halifax, Canada

      Sentiment: Strong Buy

    • Earnings in March following increased reimbursement amounts and trial data in May. Several key items to look forward to for CMXI

      Sentiment: Buy

    • Trial data in May and earnings with hopefully forward guidance in March. CMXI has a few near term items to look forward to.

      Sentiment: Buy

 
CMXI
0.34-0.01(-2.86%)Nov 13 3:59 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.